Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
This analysis highlights how intensive multifactorial management and glycemic control influence diabetic retinopathy onset, emphasizing the risks associated with hypoglycemia despite good glycemic control.
THEIA trial evaluated intravenous alteplase against oral aspirin in acute CRAO within 4.5 hours; no significant visual improvement difference was found, emphasizing the need for further research and meta-analyses to clarify thrombolysis ben
This review synthesizes current evidence from large cohorts, meta-analyses, and randomized trials evaluating metformin’s association with AMD development and progression, highlighting a nuanced but inconclusive protective potential re
The RESTORE-1 phase 3 trial demonstrates that IBI311 significantly improves proptosis and inflammation in Chinese patients with active thyroid eye disease, with a favorable safety profile.
A 38-year-old male with bilateral blurred vision and neurological symptoms was diagnosed with Vogt-Koyanagi-Harada syndrome and managed successfully with corticosteroids and immunosuppressants.
This study reveals that socioeconomic status, residential location, and household composition significantly affect treatment outcomes and follow-up in newly diagnosed POAG patients, highlighting the need for targeted strategies to improve g
This review synthesizes evidence on the incidence of acute angle closure (AAC) following pharmacologic pupillary dilation in a large teleretinal screening program, confirming the very low risk and supporting dilation safety in diverse popul
A UK study reveals most patients with geographic atrophy are open to intravitreal complement inhibitor injections if these treatments offer vision improvement, highlighting the vital role of functional benefits in therapy acceptance.
This study compares atropine and cyclopentolate for cycloplegia in preschoolers, finding atropine leads to less myopic refraction and may reduce premyopia overestimation. It highlights implications for precise refractive diagnosis in young
A recent randomized, double-blind trial demonstrates that oral lamivudine significantly improves visual acuity in patients with center-involved diabetic macular edema, offering a cost-effective and safer alternative to conventional anti-VEG
A novel deep learning model predicted retinal nerve fiber layer thickness from optic disc photos, enabling risk stratification for primary open-angle glaucoma in ocular hypertension patients, with baseline and longitudinal changes strongly
Deep learning models predicting RNFL thickness from optic disc photographs can identify ocular hypertension patients at higher risk for primary open-angle glaucoma, enhancing early risk assessment and monitoring disease progression.
A recent randomized clinical trial demonstrates that diversified segmental defocus optimization (DSDO) spectacle lenses significantly reduce the onset and progression of myopia in children, with or without adjunct low-dose atropine.
Low-level light therapy, administered perioperatively, significantly reduces dry eye symptoms and preserves ocular surface integrity after cataract surgery, offering a noninvasive adjunct to standard care.
The MI-SIGHT telemedicine program significantly improves vision and eye health outcomes by providing glaucoma and eye disease screening with care navigation in community health centers, demonstrating high satisfaction and cost-effectiveness
A large UK Biobank study demonstrates that poor sleep, low physical activity, and high sedentary behavior independently and jointly increase cataract risk, with lifestyle modifications reducing incidence.
A large retrospective study found that diabetic patients using metformin for at least five consecutive years have a significantly lower risk of developing age-related macular degeneration, especially the dry type.
UCLA engineers and ophthalmologists mapped segmental, task-dependent activation of the orbicularis oculi during five closure behaviors, defining a roadmap for targeted neurostimulation to restore protective blinking in patients with eyelid
Alcon introduces Tryptyr, the first TRPM8 agonist eye drop, promising rapid tear production for dry eye disease. FDA-approved in May 2024 following robust phase 3 trials.
The FDA has approved Vizz, a once-daily aceclidine ophthalmic solution, for presbyopia in adults based on robust phase 3 data. The eye drop offers up to 10 hours of improved near vision with a favorable safety profile.
Open language-specific specialty feeds and department pages.